logo
Plus   Neg
Share
Email

Roche: Updated Data Confirms Tecentriq With Avastin Substantially Improves Overall Survival In HCC

Roche (RHHBY) said it will present updated overall survival data from the phase III IMbrave150 study evaluating Tecentriq in combination with Avastin, compared with sorafenib, in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy. After a median follow-up of 15.6 months, the updated analysis showed that Tecentriq in combination with Avastin reduced the risk of death by 34%, with a median overall survival of 19.2 months, compared with 13.4 months for sorafenib.

The company said the updated overall survival, along with progression free survival and objective response rate results, were consistent with the primary analysis and support the use of the combination in HCC.

"These results show that Tecentriq in combination with Avastin provides the longest survival that we've ever seen in a front-line phase III study in unresectable hepatocellular carcinoma," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Kingdom's Competition and Markets Authority (CMA) has launched an investigation into technology giant Apple Inc. (AAPL) following complaints that its terms and conditions for app developers are unfair and anti-competitive. iPhone maker Apple also operates the App Store, which is the only... Supermarket chain Kroger Co. on Thursday reported that it posted a loss for the fourth quarter compared to a profit last year, hurt by pension plan withdrawal liabilities. Adjusted earnings per share topped analysts' estimates, while quarterly revenues missed it. However, the company initiated adjusted earning guidance for the full-year 2021, well above analysts' estimates. Retail sales are projected to grow at a potentially record rate during 2021, but the ongoing COVID-19 pandemic remains the biggest challenge for the year, according to the National Retail Federation. "There is no doubt the economy is positioned for growth in 2021, but how much growth comes down to a single non-economic force - the coronavirus," NRF Chief Economist Jack Kleinhenz said.
Follow RTT